A multi-center phase II study of chemotherapy (SOX) plus tislelizumab as first-line therapy for gastric cancer with liver metastasis.
Muxing Kang(Second Affiliated Hospital of Zhejiang University), J Chen(Second Affiliated Hospital of Zhejiang University), X D Liu(Beijing University of Technology), Qingqu Guo(Second Affiliated Hospital of Zhejiang University), Haiming Wu(Shanxi Medical University), GuoFeng Chen(Second Affiliated Hospital of Zhejiang University), Dan Wu(Second Affiliated Hospital of Zhejiang University), Xiaoli Jin(Second Affiliated Hospital of Zhejiang University)
Cited by 0
Related Papers
Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017
|BMJ Open|2020|121
A novel prognostic signature of immune‐related genes for patients with colorectal cancer
|Journal of Cellular and Molecular Medicine|2020|67
Electroacupuncture or transcutaneous electroacupuncture for postoperative ileus after abdominal surgery: A systematic review and meta-analysis
|International Journal of Surgery|2019|60
Actuarial Applications of Multivariate Two-Part Regression Models
|Annals of Actuarial Science|2013|56
Identification of antitumor constituents in curcuminoids from Curcuma longa L. based on the composition–activity relationship
|Journal of Pharmaceutical and Biomedical Analysis|2012|53